Buy & Sell GSK plc (GSK) – GSK plc Price Today
Aura AI Summary
Key Stats
- $102.76BMarket Cap
- HealthSector
- -17.2%3M Drawdown
- $123.59BEnterprise Value
- 3.52%Dividend Yield
- 4% Buy | 96% SellTrading Activity
- 85 daysTypical Hold Time
GSK plc (GSK) is currently valued at a market capitalization of $102.76B, with an enterprise value of $123.59B. Over the past 52 weeks, GSK plc has traded between a low of $36.2 and a high of $61.18, highlighting its annual price range. Over the past three months, GSK plc has recorded a drawdown of -17.2%, reflecting recent price volatility. GSK plc offers a dividend yield of 3.52%, with the most recent dividend of $0.46 paid on 15 May 26. On average, investors hold GSK plc for approximately 85 days, indicating typical investor behavior on the platform.
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Most Recent News
US government buys 10% stake in mining firms, signaling a new strategic investment trend.
In early 2026, the US government began acquiring stakes in American mining companies, including a 10% share in USA Rare Earth to support critical mineral projects. This move follows similar investments in Lithium Americas and Trilogy Metals, which sa...
FDA approves Sanofi's Tzield as first disease-modifying therapy for stage 3 type 1 diabetes in children.
The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). This is the first disease-modifying therapy aimed at delaying the decline of insulin produc...
FDA approves Sanofi's Tzield as first disease-modifying therapy for newly diagnosed stage 3 type 1 diabetes in children.
The FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). Tzield slows the decline of the body's insulin production by targeting the autoimmune process c...